Respiratory Infections News

Although clinical and cycle threshold value assessment can distinguish COVID-19 reinfection from detecting virus from a prior infection, it failed to identify 33% of genomically supported reinfections, according to a recent study.

For adults in the U.K., preexisting neuropsychiatric conditions and having a prescription for a related treatment carried a significantly increased risk of severe outcomes from COVID-19 and other severe acute respiratory infections.

SARS-CoV-2-related neurologic effects endured among children and adolescents in the United States who were hospitalized in 2021 for COVID-19 or multisystem inflammatory syndrome, researchers reported in JAMA Neurology.

Boston-area school districts that lifted mask mandates earlier this year experienced nearly 45 more cases of COVID-19 per 1,000 students and staff than school districts that kept their mandates in place, a study found.

Social determinants of health, including lower socioeconomic status and a higher proportion of racially minoritized groups, correlated with higher likelihood of COVID-19-related death, according to a recent study in Clinical Infectious Diseases.

Respiratory tract and total body burden of SARS-CoV-2 infection could predict how long patients will take to recover and provide insight into long COVID, according to a recent study published in Clinical Infectious Diseases.

Novavax on Monday said that its omicron subvariant vaccine candidate and original COVID-19 vaccine both performed well in a phase 3 trial testing three vaccines as a second booster dose.

CHICAGO — COVID-19-induced hyposmia eliminated odor-induced migraine headaches in an older adult, a case study presented at the 2022 American Neurological Association’s annual meeting showed.

CHICAGO — Igor J. Koralnik, MD, discusses highlights from his presentation at the 2022 American Neurological Association’s annual meeting on long COVID and its effect on the nervous system.

Pfizer and BioNTech said Friday that their bivalent COVID-19 booster, which targets the original strain of SARS-CoV-2 and the omicron BA.4 and BA.5 sublineages, elicits stronger immune responses than their original vaccine.